Access the full text.
Sign up today, get DeepDyve free for 14 days.
C Loewenstein (1907)
Die Entwicklung der HypophysisadenomeEin Beitr Lehre Geschwülsten, 188
M. Shibuya (2018)
Welcoming the new WHO classification of pituitary tumors 2017: revolution in TTF-1-positive posterior pituitary tumorsBrain Tumor Pathology, 35
J. Oriola, T. Lúcas, I. Halperin, M. Mora, M. Perales, C. Alvarez-Escola, de Paz, G. Soto, I. Salinas, M. Julian, I. Olaizola, I. Bernabéu, M. Marazuela, M. Puig-Domingo (2012)
Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues.European journal of endocrinology, 168 1
K. Kovacs, B. Scheithauer, É. Horváth, R. Lloyd (1996)
The world health organization classification of adenohypophysial neoplasms: A proposed five‐tier schemeCancer, 78
O. Mete, O. Mete, O. Mete, M. Lopes (2017)
Overview of the 2017 WHO Classification of Pituitary TumorsEndocrine Pathology, 28
A. Daly, Maria Tichomirowa, P. Petrossians, E. Heliövaara, M. Jaffrain-Rea, A. Barlier, L. Naves, T. Ebeling, A. Karhu, A. Raappana, L. Cazabat, E. Menis, C. Montañana, G. Raverot, Robert Weil, Timo Sane, D. Maiter, Sebastian Neggers, M. Yaneva, A. Tabarin, E. Verrua, E. Eloranta, A. Murat, O. Vierimaa, P. Salmela, P. Emy, R. Toledo, M. Sabate, Chiara Villa, M. Popelier, R. Salvatori, Juliet Jennings, Á. Longás, J. Aizpún, M. Georgitsi, Ralf Paschke, C. Ronchi, Matti Valimaki, C. Saloranta, W. Herder, Renato Cozzi, M. Guitelman, Flavia Magri, M. Lagonigro, Georges Halaby, Vinciane Corman, M. Hagelstein, J. Vanbellinghen, G. Barra, A. Gimenez-Roqueplo, F. Cameron, F. Borson‐Chazot, I. Holdaway, S. Toledo, G. Stalla, A. Spada, S. Zacharieva, J. Bertherat, T. Brue, V. Bours, P. Chanson, L. Aaltonen, A. Beckers (2010)
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study.The Journal of clinical endocrinology and metabolism, 95 11
W. Selman, E. Laws, B. Scheithauer, S. Carpenter (1986)
The occurrence of dural invasion in pituitary adenomas.Journal of neurosurgery, 64 3
R. Lloyd, R. Osamura (1997)
Transcription factors in normal and neoplastic pituitary tissuesMicroscopy Research and Technique, 39
G. Raverot, A. Vasiljevic, E. Jouanneau, J. Trouillas (2015)
A prognostic clinicopathologic classification of pituitary endocrine tumors.Endocrinology and metabolism clinics of North America, 44 1
K. Thapar, K. Kovacs, E. Laws (1995)
The classification and molecular biology of pituitary adenomas.Advances and technical standards in neurosurgery, 22
D. Cote, T. Smith, C. Sandler, Tina Gupta, T. Bale, W. Bi, I. Dunn, U. Girolami, W. Woodmansee, U. Kaiser, E. Laws (2016)
Functional Gonadotroph Adenomas: Case Series and Report of Literature.Neurosurgery
G. Raverot, E. Dantony, Julie Beauvy, A. Vasiljevic, S. Mikolasek, F. Borson‐Chazot, E. Jouanneau, P. Roy, J. Trouillas (2017)
Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five‐Tiered ClassificationThe Journal of Clinical Endocrinology & Metabolism, 102
Sylvia Asa, O. Casar-Borota, Philippe Chanson, Etienne Delgrange, P. Earls, S. Ezzat, Ashley Grossman, H. Ikeda, N. Inoshita, N. Karavitaki, M. Korbonits, Edward Laws, Lopes Mb, N. Maartens, Ian McCutcheon, O. Mete, Hiroshi Nishioka, G. Raverot, Federico Roncaroli, W. Saeger, L. Syro, A. Vasiljevic, Chiara Villa, A. Wierinckx, J. Trouillas (2017)
From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal.Endocrine-related cancer, 24 4
B. Meij, M. Lopes, D. Ellegala, T. Alden, E. Laws (2002)
The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.Journal of neurosurgery, 96 2
G. Raverot, P. Burman, A. McCormack, A. Heaney, S. Petersenn, V. Popović, J. Trouillas, O. Dekkers (2018)
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.European journal of endocrinology, 178 1
J. Trouillas, P. Roy, N. Sturm, E. Dantony, C. Cortet-Rudelli, G. Viennet, J. Bonneville, R. Assaker, C. Auger, T. Brue, A. Cornélius, H. Dufour, E. Jouanneau, P. François, F. Galland, F. Mougel, F. Chapuis, L. Villeneuve, C. Maurage, D. Figarella-Branger, G. Raverot, The Hypopronos (2013)
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-upActa Neuropathologica, 126
L. Kasuki, L. Neto, L. Wildemberg, L. Colli, M. Castro, C. Takiya, M. Gadelha (2012)
AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression.Endocrine-related cancer, 19 3
F. Caimari, L. Hernández-Ramírez, M. Dang, P. Gabrovska, D. Iacovazzo, K. Stals, S. Ellard, M. Korbonits (2018)
Risk category system to identify pituitary adenoma patients with AIP mutationsJournal of Medical Genetics, 55
MB Lopes, BW Scheithauer, D Schiff (2005)
Pituitary carcinoma: diagnosis and treatmentEndocrine, 28
M. Lopes, B. Scheithauer, D. Schiff (2005)
Pituitary carcinomaEndocrine, 28
K. Thapar, K. Kovacs, B. Scheithauer, L. Ştefăneanu, É. Horváth, P. Pernicone, David Murray, E. Laws (1996)
Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody.Neurosurgery, 38 1
C Benda (1901)
Die mikroscopische Befunde bei vier Fallen von AkromegalieDtsch Med Wochenschr, 27
L. Perez-Rivas, M. Reincke (2015)
Genetics of Cushing’s disease: an updateJournal of Endocrinological Investigation, 39
J. Balogun, E. Monsalves, Kyle Juraschka, K. Parvez, W. Kucharczyk, O. Mete, F. Gentili, G. Zadeh (2015)
Null Cell Adenomas of the Pituitary Gland: an Institutional Review of Their Clinical Imaging and Behavioral CharacteristicsEndocrine Pathology, 26
K. Friend, Y. Chiou, E. Laws, M. Lopes, M. Shupnik (1993)
Pit-1 messenger ribonucleic acid is differentially expressed in human pituitary adenomas.The Journal of clinical endocrinology and metabolism, 77 5
K. Øystese, O. Casar-Borota, K. Normann, M. Zucknick, J. Berg, J. Bollerslev (2017)
Estrogen Receptor &agr;, a Sex‐Dependent Predictor of Aggressiveness in Nonfunctioning Pituitary Adenomas: SSTR and Sex Hormone Receptor Distribution in NFPAThe Journal of Clinical Endocrinology & Metabolism, 102
S. Asa, A. Bamberger, B. Cao, M. Wong, K. Parker, S. Ezzat (1996)
The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph.The Journal of clinical endocrinology and metabolism, 81 6
M. Lopes (2017)
The 2017 World Health Organization classification of tumors of the pituitary gland: a summaryActa Neuropathologica, 134
B. Scheithauer, T. Gaffey, R. Lloyd, T. Sebo, K. Kovacs, É. Horváth, Ö. Yapıcıer, W. Young, F. Meyer, Tamatsu Kuroki, Darren Riehle, E. Laws (2006)
Pathobiology of Pituitary Adenomas and CarcinomasNeurosurgery, 59
G. Zada, W. Woodmansee, S. Ramkissoon, J. Amadio, V. Nosé, E. Laws (2011)
Atypical pituitary adenomas: incidence, clinical characteristics, and implications.Journal of neurosurgery, 114 2
B. Scheithauer, K. Kovacs, E. Laws, R. Randall (1986)
Pathology of invasive pituitary tumors with special reference to functional classification.Journal of neurosurgery, 65 6
Justin Seltzer, Charles Ashton, Thomas Scotton, D. Pangal, J. Carmichael, G. Zada (2015)
Gene and protein expression in pituitary corticotroph adenomas: a systematic review of the literature.Neurosurgical focus, 38 2
H. Gittleman, Q. Ostrom, Paul Farah, A. Ondracek, Yanwen Chen, Yingli Wolinsky, C. Kruchko, J. Singer, V. Kshettry, E. Laws, A. Sloan, W. Selman, J. Barnholtz-Sloan (2014)
Descriptive epidemiology of pituitary tumors in the United States, 2004-2009.Journal of neurosurgery, 121 3
H. Zaidi, D. Cote, I. Dunn, E. Laws (2016)
Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomasJournal of Clinical Neuroscience, 34
(2020)
Pituitary HyperplasiaDefinitions
Q. Ostrom, H. Gittleman, Paul Farah, A. Ondracek, Yanwen Chen, Yingli Wolinsky, N. Stroup, C. Kruchko, J. Barnholtz-Sloan (2013)
CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.Neuro-oncology, 15 Suppl 2
K. Thapar, B. Scheithauer, K. Kovacs, P. Pernicone, E. Laws (1996)
p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.Neurosurgery, 38 4
Q. Ostrom, H. Gittleman, Peter Liao, Chaturia Rouse, Yanwen Chen, J. Dowling, Yingli Wolinsky, C. Kruchko, J. Barnholtz-Sloan (2012)
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.Neuro-oncology, 16 Suppl 4
K. Kovacs, É. Horváth (1977)
Pathology of pituitary adenomas.Bulletin of the Los Angeles neurological societies, 42 3-4
J Erdheim (1903)
Zur normalen und pathologischen Histologie der Glandula thyreoidea, parathyroidea und HypophysisBeitr pathol Anat, 33
M. Mason, K. Friend, J. Copper, M. Shupnik (1993)
Pit-1/GHF-1 binds to TRH-sensitive regions of the rat thyrotropin beta gene.Biochemistry, 32 34
K. Thapar, K. Kovacs, E. Laws, P. Muller (1993)
Pituitary Adenomas: Current Concepts in Classification, Histopathology, and Molecular BiologyEndocrinologist, 3
J Trouillas, C Girod (1996)
Pituitary adenomas
Dr. Löwenstein (1907)
Die Entwicklung der HypophysisadenomeVirchows Archiv für pathologische Anatomie und Physiologie und für klinische Medizin, 188
Background Pituitary tumors are common lesions, and they represent the second most frequent primary brain tumor. Their classification has undergone several changes over time. The World Health Organization conducts periodic expert review/ consensus meetings and publishes the results as recommendations for changes in classification, based on advances in molecular and genetic advances. This paper summarizes the results of the 2017 WHO Classification, which recommends several important changes. Purpose This paper provides a review of the major changes and issues leading to an understanding of the basis for a new pituitary tumor classification. They include the rejection and modification of prior conceptual and pathological characteristics of these neoplasms. There is also considerable concern related to invasive and recurrent pituitary tumors which follow a less benign course than the typical pituitary adenoma. Methods A review of the outcome data for the previously designated “atypical” pituitary tumor category revealed that the former criteria were not adequate to support their ability to predict with accuracy the clinical course of a given tumor. A similar review was accomplished regarding the role of the p53 tumor suppressor mutation. Again, there was no reliable contribution of p53 status to tumor aggressiveness. Other changes have occurred regarding
Journal of Endocrinological Investigation – Springer Journals
Published: Jun 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.